Scpharmaceuticals Short Long Term Debt Total from 2010 to 2025

SCPH Stock  USD 3.28  0.14  4.09%   
Scpharmaceuticals' Short and Long Term Debt Total is increasing with slightly volatile movements from year to year. Short and Long Term Debt Total is predicted to flatten to about 24.9 M. For the period between 2010 and 2025, Scpharmaceuticals, Short and Long Term Debt Total quarterly trend regression had mean deviation of  9,177,773 and range of 35 M. View All Fundamentals
 
Short and Long Term Debt Total  
First Reported
2017-09-30
Previous Quarter
41.4 M
Current Value
52.5 M
Quarterly Volatility
12.4 M
 
Covid
Check Scpharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Scpharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 502.9 K, Interest Expense of 9.8 M or Selling General Administrative of 64.4 M, as well as many indicators such as Price To Sales Ratio of 14.22, Dividend Yield of 0.0 or PTB Ratio of 6.13. Scpharmaceuticals financial statements analysis is a perfect complement when working with Scpharmaceuticals Valuation or Volatility modules.
  
Check out the analysis of Scpharmaceuticals Correlation against competitors.
For more detail on how to invest in Scpharmaceuticals Stock please use our How to Invest in Scpharmaceuticals guide.

Latest Scpharmaceuticals' Short Long Term Debt Total Growth Pattern

Below is the plot of the Short Long Term Debt Total of Scpharmaceuticals over the last few years. It is Scpharmaceuticals' Short and Long Term Debt Total historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Scpharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
Short Long Term Debt Total10 Years Trend
Slightly volatile
   Short Long Term Debt Total   
       Timeline  

Scpharmaceuticals Short Long Term Debt Total Regression Statistics

Arithmetic Mean19,315,218
Geometric Mean16,765,663
Coefficient Of Variation61.28
Mean Deviation9,177,773
Median11,344,000
Standard Deviation11,835,515
Sample Variance140.1T
Range35M
R-Value0.78
Mean Square Error57.8T
R-Squared0.61
Significance0.0003
Slope1,949,017
Total Sum of Squares2101.2T

Scpharmaceuticals Short Long Term Debt Total History

202524.9 M
202446.3 M
202340.3 M
202237.4 M
202117.6 M
202020.2 M
201920.3 M

About Scpharmaceuticals Financial Statements

Investors use fundamental indicators, such as Scpharmaceuticals' Short Long Term Debt Total, to determine how well the company is positioned to perform in the future. Although Scpharmaceuticals' investors may analyze each financial statement separately, they are all interrelated. Understanding these patterns can help investors make the right trading decisions.
Last ReportedProjected for Next Year
Short and Long Term Debt Total46.3 M24.9 M

Currently Active Assets on Macroaxis

When determining whether Scpharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Scpharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Scpharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Scpharmaceuticals Stock:
Check out the analysis of Scpharmaceuticals Correlation against competitors.
For more detail on how to invest in Scpharmaceuticals Stock please use our How to Invest in Scpharmaceuticals guide.
You can also try the Bonds Directory module to find actively traded corporate debentures issued by US companies.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Scpharmaceuticals. If investors know Scpharmaceuticals will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Scpharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.95)
Revenue Per Share
0.741
Quarterly Revenue Growth
1.641
Return On Assets
(0.42)
Return On Equity
(1.67)
The market value of Scpharmaceuticals is measured differently than its book value, which is the value of Scpharmaceuticals that is recorded on the company's balance sheet. Investors also form their own opinion of Scpharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Scpharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Scpharmaceuticals' market value can be influenced by many factors that don't directly affect Scpharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Scpharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Scpharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Scpharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.